LC
CVAC

Lindbrook Capital’s CureVac CVAC Stock Holding History

Lindbrook Capital’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$5.22K Sell
1,884
-1,430
-43% -$4.97K ﹤0.01% 1936
2024
Q4 		$11.3K Sell
3,314
-4,728
-59% -$13.6K ﹤0.01% 1592
2024
Q3 		$23.6K Sell
8,042
-1,142
-12% -$3.76K ﹤0.01% 1205
2024
Q2 		$31.2K Buy
9,184
+4,269
+87% +$14K ﹤0.01% 997
2024
Q1 		$14.9K Buy
4,915
+3,539
+257% +$12.4K ﹤0.01% 1364
2023
Q4 		$5.79K Sell
1,376
-279
-17% -$1.51K ﹤0.01% 1808
2023
Q3 		$11.3K Buy
1,655
+31
+2% +$274 ﹤0.01% 1348
2023
Q2 		$16.9K Buy
1,624
+576
+55% +$5.15K ﹤0.01% 1183
2023
Q1 		$7.3K Buy
1,048
+250
+31% +$2.18K ﹤0.01% 1655
2022
Q4 		$4.81K Buy
798
+334
+72% +$2.47K ﹤0.01% 1846
2022
Q3 		$4K Buy
464
+299
+181% +$3.49K ﹤0.01% 1743
2022
Q2 		$2K Sell
165
-441
-73% -$7.29K ﹤0.01% 1935
2022
Q1 		$12K Buy
606
+243
+67% +$4.85K ﹤0.01% 1208
2021
Q4 		$12K Buy
+363
New +$14.6K ﹤0.01% 1196

Other funds holding CVAC

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Lindbrook Capital's CVAC Position: Q1 2025 in Review

Lindbrook Capital reduced its CureVac (CVAC) stake by 43% in Q1 2025, selling an estimated $4.97K and leaving 1,884 shares worth $5.22K. The position accounts for ﹤0.01% of the portfolio, ranked #1936.

Lindbrook Capital first reported a position in CVAC in Q4 2021 and has held it in 14 quarters since. The position peaked at $31.2K in Q2 2024. 83 funds tracked by Wall St. Rank hold CVAC as of Q1 2025.

  • Lindbrook Capital held 1,884 shares of CureVac worth $5.22K as of Q1 2025.
  • Lindbrook Capital sold 1,430 CureVac shares in Q1 2025, an estimated $4.97K.
  • CureVac made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1936 holding.
  • Lindbrook Capital first reported a position in CureVac in Q4 2021 and has held it in 14 quarters since.
  • Lindbrook Capital's CureVac position peaked at $31.2K in Q2 2024.
  • 83 funds tracked by Wall St. Rank held CureVac as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.